A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease
Julia Z Xu,Anna Conrey,Ingrid Frey,Eveline Gwaabe,Laurel A Menapace,Laxminath Tumburu,Maureen Lundt,Timothy Lequang,Quan Li,Kristen Glass,Emily B Dunkelberger,Varsha Iyer,Heidi Mangus,Charles Kung,Lenny Dang,Penelope A Kosinski,Peter Hawkins,Neal Jeffries,William A Eaton,Swee Lay Thein,Julia Zhe Xu,Anna K Conrey,Ingrid C Frey,Laurel Anne Menapace,Kristen E Glass
DOI: https://doi.org/10.1182/blood.2022015403
IF: 20.3
2022-05-18
Blood
Abstract:We established proof of concept for activating pyruvate kinase in sickle cell disease (SCD) as a viable therapeutic approach. Mitapivat, a PK activator, improved hematologic parameters, increased oxygen affinity, and reduced sickling in patients with SCD anemia. Polymerization of deoxygenated hemoglobin S (HbS) underlies the pathophysiology of sickle cell disease (SCD). In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis. Both changes have therapeutic potential for patients with SCD. Here, we evaluated the safety and tolerability of multiple ascending doses of mitapivat in adults with SCD (HbSS) with no recent blood transfusions or changes in hydroxyurea (HU) or L-glutamine therapy. Seventeen subjects were enrolled, 1 subject was withdrawn shortly after starting the study. Sixteen subjects completed 3 ascending dose levels of mitapivat (5 mg, 20 mg and 50 mg, twice daily (BID)) for 2 weeks each; following a protocol amendment, the dose was escalated to 100 mg BID in 9 subjects. Mitapivat was well-tolerated at all dose levels, with the most common treatment-emergent adverse events (AEs) being insomnia, headache, and hypertension. Six serious AEs (SAEs) included 4 vaso-occlusive crises (VOCs), non-VOC-related shoulder pain, and a pre-existing pulmonary embolism. Two VOCs occurred during drug taper and were possibly drug-related; no other SAEs were drug-related. Mean hemoglobin increase at the 50 mg BID dose level was 1.2 g/dL, with 9/16 (56.3%) patients achieving a hemoglobin response of ≥ 1 g/dL increase compared to baseline. Mean reductions in hemolytic markers and dose-dependent decreases in 2,3-DPG and increases in ATP were also observed. This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD. (Investigator-sponsor; ClinicalTrials.gov NCT04000165).
hematology